Scholarlink

Background <p>Clinical pharmacokinetic data on clazosentan, an endothelin receptor antagonist, after aneurysmal subarachnoid hemorrhage (SAH), particularly data on cerebrospinal fluid (CSF), remain limited. In this study, we evaluated the plasma and CSF concentrations and CSF penetration rate of clazosentan over time, and investigated whether the temporal profile differed between patients with SAH with and without delayed cerebral ischemia (DCI).</p> Methods <p>Clinical data, plasma, and CSF samples from 37 patients (mean, 63.2&#xa0;years) with aneurysmal SAH prospectively collected in the SeCAS registry (nine stroke centers in Mie Prefecture, Japan, 2023–2025) were retrospectively analyzed. All patients underwent aneurysm obliteration within 48&#xa0;h of SAH onset and were subsequently treated with continuous intravenous clazosentan (10&#xa0;mg/h), with simultaneous collection of plasma and CSF over time. Clazosentan concentrations in plasma and CSF at post-SAH days 0–3, 4–6, 7–9, and 10–12 were measured by quantitative liquid chromatography–tandem mass spectrometry, and the CSF penetration rate was calculated. Mixed-effect models for repeated measures were used to assess temporal changes and period-by-DCI interactions.</p> Results <p>DCI occurred in seven patients (18.9%). In the overall cohort, plasma clazosentan concentrations decreased over time (<i>p</i> = 0.010). CSF concentrations showed no significant temporal change (<i>p</i> = 0.190), whereas the CSF penetration rate increased over time (<i>p</i> &lt; 0.001). The temporal profile of CSF penetration rate differed by DCI status (period-by-DCI interaction, <i>p</i> = 0.008). In pairwise comparisons, the CSF penetration rate at post-SAH days 10–12 was significantly lower in the DCI group (geometric mean ratio 0.3, 95% confidence interval 0.1–0.7, <i>p</i> = 0.008).</p> Conclusions <p>During continuous intravenous infusion of clazosentan after SAH, plasma clazosentan concentrations declined while CSF concentrations were maintained, resulting in an increased CSF penetration rate. Lower CSF penetration was observed at days 10–12 in patients who developed DCI, suggesting a potential association between the relative CSF exposure of clazosentan and DCI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma and Cerebrospinal Fluid Pharmacokinetics of Clazosentan and its Relationship to Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Koichi Hakozaki,
  • Kazuaki Aoki,
  • Fumihiro Kawakita,
  • Hidehisa Sekijima,
  • Hirokazu Kotani,
  • Hidenori Suzuki,
  • Yasuyuki Umeda,
  • Katsuhiro Tanaka,
  • Yoichi Miura,
  • Yusuke Kamei,
  • Takanori Sano,
  • Tomohiro Araki,
  • Masato Shiba,
  • Naoki Ichikawa,
  • Shigetoshi Shimizu,
  • Takuro Tsuchiya,
  • Reona Asada,
  • Hidenori Suzuki,
  • Naoki Toma,
  • Ryuta Yasuda,
  • Fumihiro Kawakita,
  • Hirofumi Nishikawa,
  • Hideki Kanamaru,
  • Yotaro Kitano,
  • Yume Suzuki,
  • Fujimaro Ishida,
  • Keiji Fukazawa,
  • Kazuhiko Tsuda,
  • Yu Sato,
  • Hideki Nakajima,
  • Seiji Hatazaki,
  • Kazuhide Hamada,
  • Mai Nampei,
  • Fumitaka Miya,
  • Hiroshi Tanemura,
  • Masashi Fujimoto

摘要

Background

Clinical pharmacokinetic data on clazosentan, an endothelin receptor antagonist, after aneurysmal subarachnoid hemorrhage (SAH), particularly data on cerebrospinal fluid (CSF), remain limited. In this study, we evaluated the plasma and CSF concentrations and CSF penetration rate of clazosentan over time, and investigated whether the temporal profile differed between patients with SAH with and without delayed cerebral ischemia (DCI).

Methods

Clinical data, plasma, and CSF samples from 37 patients (mean, 63.2 years) with aneurysmal SAH prospectively collected in the SeCAS registry (nine stroke centers in Mie Prefecture, Japan, 2023–2025) were retrospectively analyzed. All patients underwent aneurysm obliteration within 48 h of SAH onset and were subsequently treated with continuous intravenous clazosentan (10 mg/h), with simultaneous collection of plasma and CSF over time. Clazosentan concentrations in plasma and CSF at post-SAH days 0–3, 4–6, 7–9, and 10–12 were measured by quantitative liquid chromatography–tandem mass spectrometry, and the CSF penetration rate was calculated. Mixed-effect models for repeated measures were used to assess temporal changes and period-by-DCI interactions.

Results

DCI occurred in seven patients (18.9%). In the overall cohort, plasma clazosentan concentrations decreased over time (p = 0.010). CSF concentrations showed no significant temporal change (p = 0.190), whereas the CSF penetration rate increased over time (p < 0.001). The temporal profile of CSF penetration rate differed by DCI status (period-by-DCI interaction, p = 0.008). In pairwise comparisons, the CSF penetration rate at post-SAH days 10–12 was significantly lower in the DCI group (geometric mean ratio 0.3, 95% confidence interval 0.1–0.7, p = 0.008).

Conclusions

During continuous intravenous infusion of clazosentan after SAH, plasma clazosentan concentrations declined while CSF concentrations were maintained, resulting in an increased CSF penetration rate. Lower CSF penetration was observed at days 10–12 in patients who developed DCI, suggesting a potential association between the relative CSF exposure of clazosentan and DCI.